Simon Lévesque

Aug 30, 2023 | biorxiv.org | Frederic Grenier |Simon Lévesque |Sébastien Rodrigue |Louis-Patrick Haraoui

AbstractTigecycline is an antibiotic of last resort for infections with carbapenem-resistant Acinetobacter baumannii. Plasmids harboring variants of the tetracycline destructase tet(X) promote rising tigecycline resistance rates. We report the earliest observation of tet(X3) in a clinical strain predating tigecycline's commercialization, suggesting selective pressures other than tigecycline contributed to its emergence. Competing Interest StatementThe authors have declared no competing interest.